Glaukos CDO Tomas Navratil sells $10.6 million in company shares
What it means
- What to watch: The headline hangs on one number ($10.6 million) — one data point is a snapshot, so the trailing trend is the context it needs.
- How the stock is trading: $GKOS -2.33% in the latest session.
- Timing: It landed while New York slept, so the session change beside it belongs to a day that had already closed. Market holidays are not detected.
Where the stock stands
$GKOS last changed hands at $233.04, -2.33% on the session, 6.3% below its 52-week high of $248.75 and 188% above its low of $80.91 — within a tenth of its 52-week high. Over the year it has ranged 207% from low to high: a very wide band; big swings are routine for this one, not news. These are latest-session quotes, not live prices — the live tape is on the $GKOS page.
How much coverage it is getting
Wook has logged 4 stories on $GKOS in the last 30 days, 2 of them this week. At its 30-day pace you would expect about 1 a week, so this week is running well ahead of normal; the press has found a reason to keep writing. Across those stories 0 read bullish, 4 neutral and 0 bearish. This one reads neutral, so it sits squarely with the crowd. 2 of the 4 (50%) came from Investing.com itself, so the count says as much about how often Investing.com hits publish as about how much attention there is — the other outlets are the better gauge. 12 related stories from the same name or desk are listed beside this one.
The bigger picture
In healthcare, the calendar is the catalyst — trial readouts, FDA decisions and pricing rules. One result can move a single drugmaker sharply; a policy change moves the whole aisle. Wook's supply-chain scanner has Health Care reading calm today: no unusual stress in the filings and disclosures it watches.
Coming up
$GKOS earnings today. These were on the calendar before this story and are not caused by it, but the nearest is close enough that the hard numbers get the last word soon.
What to watch next
The $GKOS page has the full chart, the filings and the valuation model behind every figure here. Because one outlet dominates the coverage, reading another outlet on the same story is the quickest check on whether it is being confirmed or just repeated. And Wook AI, up top, will happily do the math — how far $GKOS sits from its high, or how this week's coverage stacks up.
How this analysis was made
Investing.com published it, and Wook filed it under Healthcare & Pharma. No strongly worded term either way, so it reads neutral at low severity — a factual headline rather than a charged one. It was matched to $GKOS. It carried $10.6 million, shown as published and not recalculated. The publisher gave no preview text, and nothing has been written in to fill the gap.
The tone and severity labels come from a fixed word list — no editor, no AI, no crystal ball — so they describe how a story is worded, not what happens next. They are not a forecast or a recommendation, and a same-day move does not mean this story caused it. Not investment advice.
Discussion
No one has weighed in yet. Start the discussion on this story.